[1]顾民华,顾 勇.川芎嗪通过miR-34a对氧化型低密度脂蛋白诱导的冠状动脉内皮细胞损伤的保护作用[J].陕西中医,2023,(9):1169-1172.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.002]
　GU Minhua,GU Yong.Protective effect and mechanism of ligustrazine on coronary artery endothelial cell injury induced by oxidized low-density lipoprotein through miR-34a[J].,2023,(9):1169-1172.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.002]
点击复制

川芎嗪通过miR-34a对氧化型低密度脂蛋白诱导的冠状动脉内皮细胞损伤的保护作用
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年9期
页码:
1169-1172
栏目:
基础研究
出版日期:
2023-09-05

文章信息/Info

Title:
Protective effect and mechanism of ligustrazine on coronary artery endothelial cell injury induced by oxidized low-density lipoprotein through miR-34a
作者:
顾民华; 顾 勇
(海南省中医院心血管科,海南 海口 570203)
Author(s):
GU Minhua; GU Yong
(Department of Cardiology,Hainan Provincial Hospital of Traditional Chinese Medicine,Haikou 570203,China)
关键词:
川芎嗪;  miR-34a;  人冠状动脉内皮细胞;  炎症反应;  氧化应激;  氧化型低密度脂蛋白
Keywords:
Ligustrazine;  miR-34a;  HCAECs;  Inflammation;  Oxidative stress;  Oxidized low-density lipoprotein
分类号:
R 541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2023.09.002
文献标志码:
A
摘要:
目的:探讨川芎嗪是否通过miR-34a影响氧化型低密度脂蛋白(ox-LDL)诱导的人冠状动脉内皮细胞(HCAECs)损伤。方法:正常培养人HCAECs,作为Con组; 用50 mg/L的ox-LDL干预HCAECs,建立细胞损伤模型,作为ox-LDL组。并设立1、10、100 mmol/L组(HCAECs用1、10、100 mmol/L川芎嗪处理+ox-LDL干预),ox-LDL+anti-miR-NC组、ox-LDL+anti-miR-34a组、ox-LDL+miR-NC组、ox-LDL+miR-34a组、ox-LDL+miR-NC+100 mmol/L组、ox-LDL+miR-34a+100 mmol/L组。分别采用试剂盒、酶联免疫吸附法(ELISA)和实时荧光定量PCR(RT-qPCR)检测HCAECs中丙二醛(MDA)含量、超氧化物歧化酶(SOD)活性、肿瘤坏死因子-α(TNF-α)、白细胞介素1β(IL-1β)水平和微小核糖核酸34a(miR-34a)表达。结果:ox-LDL组HCAECs的MDA含量、TNF-α、IL-1β水平、miR-34a表达水平比Con组显著升高,SOD活力比Con组显著降低,差异有统计学意义(P<0.05); 与ox-LDL组比较,川芎嗪显著降低细胞MDA含量、TNF-α、IL-1β水平以及miR-34a表达水平,显著升高SOD活力,差异有统计学意义(P<0.05)。与ox-LDL+anti-miR-NC组比较,ox-LDL+anti-miR-34a组细胞MDA含量以及TNF-α、IL-1β水平显著降低,SOD活力显著升高,差异有统计学意义(P<0.05)。ox-LDL+miR-34a+100 mmol/L组HCAECs的MDA含量以及TNF-α、IL-1β水平显著高于ox-LDL+miR-NC+100 mmol/L组,SOD活力显著低于ox-LDL+miR-NC+100 mmol/L组,差异有统计学意义(P<0.05)。结论:川芎嗪通过抑制miR-34a降低ox-LDL诱导的人HCAECs炎症反应和氧化应激。
Abstract:
Objective:To investigate whether ligustrazine affects oxidized low-density lipoprotein(ox-LDL)-induced injury of human coronary artery endothelial cells(HCAECs)via miR-34a.Methods:Normally culture human HCAECs as the Con group.Intervene HCAECs with 50 mg/L ox-LDL to establish a cell injury model as the ox-LDL group.And set up 1,10,100 mmol/L groups(HCAECs were treated with 1,10,100 mmol/L ligustrazine + ox-LDL intervention),ox-LDL+anti-miR-NC group,ox-LDL+anti-miR-34a group,ox-LDL+miR-NC group,ox-LDL+miR-34a group,ox-LDL+miR-NC+100 mmol/L group,ox-LDL+miR-34a+100 mmol/L group.The Malondialdehyde(MDA)conten,Superoxide dismutase(SOD)activity,Tumor necrosis factor(TNF-α),Interleukin-1β(IL-1β)levels and miR-34a expression in HCAECs were detected by kits,ELISA and real-time quantitative PCR(RT-qPCR),respectively.Results:The MDA content,TNF-α,IL-1β,levels and miR-34a expression levels of HCAECs in the ox-LDL group were significantly higher than those in the Con group,and the SOD activity was significantly lower than those in the Con group(P<0.05).Compared with the ox-LDL group,ligustrazine significantly reduced the cell MDA,the content and the levels of TNF-α and IL-1β,significantly increased the activity of SOD(P<0.05).Compared with the ox-LDL+anti-miR-NC group,the cell MDA content,TNF-α and IL-1β levels in the ox-LDL+anti-miR-34a group were significantly reduced,and the SOD activity was significantly increased(P<0.05).The MDA content,TNF-α and IL-1β levels of HCAECs in the ox-LDL+miR-34a+100 mmol/L group were significantly higher than those in the ox-LDL+miR-NC+100 mmol/L group,and the SOD activity was significantly lower than that in the ox-LDL+miR-NC+100 mmol/L group(P<0.05).Conclusion:Ligustrazine can reduce ox-LDL-induced inflammatory response and oxidative stress in human HCAECs by inhibiting miR-34a.

参考文献/References:

[1] 许 璐,白春英,陈士萍,等.早发冠心病患者载脂蛋白E基因多态性分析及其与冠状动脉病变严重程度关系研究[J].陕西医学杂志,2022,51(9):1090-1093.
[2] 邢丽君,魏月娟,纪立霞,等.补脾通络方治疗冠心病微血管心绞痛疗效研究[J].陕西中医,2023,44(3):316-319.
[3] 郭晓梅,刘艳军,黄春莉.中药复方穴位贴敷联合心可舒片治疗冠心病心绞痛临床研究[J].陕西中医,2023,44(2):255-258.
[4] 凌 望,陆 萍,柴 钰,等.参归宁心合剂治疗冠心病稳定型心绞痛气阴两虚兼瘀证疗效研究[J].陕西中医,2022,43(12):1691-1693.
[5] 孙玉敏,李 绒.冠心病患者血清miR-21、miR-29a表达水平与心电图QRS波时限相关性分析[J].陕西医学杂志,2021,50(6):713-716.
[6] 宋赛赛,程 琳,贺 娇,等.外泌体miRNA与心血管疾病研究进展[J].临床和实验医学杂志,2020,30(4):107-110.
[7] 周 鑫,孙晓莹,贾礼伊,等.中药单体川芎嗪在疾病治疗中的应用与机制研究进展[J].陕西中医,2022,43(4):541-544.
[8] 郑思敏,张少博,牛晓丽,等.川芎嗪通过激活PKCα/Nrf2信号转导抑制七氟烷诱导的氧化损伤和血脑屏障破坏研究[J].陕西中医,2020,41(8):1025-1031.
[9] Zhang S,Li L,Chen W,et al.Natural products:The role and mechanism in low-density lipoprotein oxidation and atherosclerosis[J].Phytother Res,2021,35(6):2945-2967.
[10] 梁伟海,陈志宁,林国伟,等.天麻、法半夏水提物对ox-LDL诱导HUVECs损伤的影响[J].浙江中西医结合杂志,2021,31(5):402-406.
[11] 陈红伟,邢永生,王志方,等.可溶性凝集素样氧化型低密度脂蛋白受体1和锌指蛋白A20与冠心病的关系[J].中华老年心脑血管病杂志,2021,23(5):475-478.
[12] 杨桂彧.慢性肾衰竭合并冠心病患者血浆氧化型低密度脂蛋白水平变化及临床意义[J].心血管病防治知识,2020,10(19):44-46.
[13] 麦伟流,周星求,李红甜.丹参川芎嗪注射液治疗慢性肺源性心脏病急性发作期合并左心衰竭的临床效果探讨[J].临床医学工程,2020,27(5):621-622.
[14] 刘 英,程敏菊,魏鹏辉.川芎嗪缓解冠心病大鼠心肌损伤的作用及其机制[J].西北药学杂志,2023,38(3):62-67.
[15] 李 一.丹参川芎嗪注射液治疗冠心病心绞痛的效果探讨[J].当代医药论丛,2020,18(2):78-79.
[16] 李 敏,谢雁鸣,王志飞,等.基于倾向性评分的丹参川芎嗪注射液治疗冠状动脉粥样硬化性心脏病的疗效评价研究[J].国际中医中药杂志,2020,42(5):475-480.
[17] 王国峰,陆 峰,赵 霞,等.川芎嗪对氧化低密度脂蛋白诱导内皮细胞炎症反应的影响[J].中华高血压杂志,2012,20(4):347-351.
[18] 阚科佳,齐昊喆,杨硕菲,等.舒洛地特对氧化型低密度脂蛋白诱导人脐静脉内皮细胞损伤的保护作用及其机制研究[J].介入放射学杂志,2017,26(6):539-543.
[19] 刘 钰,蔡民华,王 聪,等.辣椒素对心肌缺血再灌注损伤大鼠心功能及miR-34a/SIRT1轴的影响[J].中国老年学杂志,2023,43(8):1894-1899.
[20] 黄仲略,黄菲菲,高 翔.miR-34a在高糖刺激下H9c2心肌细胞凋亡过程中的调控作用分析[J].中国循证心血管医学杂志,2022,14(4):480-483.
[21] 范 丽,姚亚妮,李 瑜.miR-34a在人H9C2心肌细胞缺氧复氧损伤中的保护作用及机制[J].中华实用诊断与治疗杂志,2020,34(3):250-253.
[22] 崔晓磊,高恒波,姚冬奇,等.miR-34a通过靶向SIRT 1蛋白调控氧化型低密度脂蛋白介导的HCAECs凋亡的研究[J].中国急救医学,2021,41(1):55-59.

相似文献/References:

[1]郑思敏,张少博,牛晓丽△,等.川芎嗪通过激活PKCα/Nrf2信号转导抑制七氟烷诱导的氧化损伤和血脑屏障破坏研究*[J].陕西中医,2020,(8):1025.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.004]
　ZHENG Simin,ZHANG Shaobo,NIU Xiaoli,et al.Ligustrazine inhibits sevoflurane-induced oxidative damage and blood-brain barrier disruption by activating PKCα/Nrf2 signaling[J].,2020,(9):1025.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.004]
[2]周 鑫,孙晓莹,贾礼伊,等.中药单体川芎嗪在疾病治疗中的应用与机制研究进展[J].陕西中医,2022,(4):541.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.034]
　ZHOU Xin,SUN Xiaoying,JIA Liyi,et al.Research progress on application and mechanism of traditional Chinese medicine tetramethylpyrazine in disease treatment[J].,2022,(9):541.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.034]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82160899); 海南省自然科学基金资助项目(821RC1128)
更新日期/Last Update: 2023-09-08